90Y-2IT-BAD-Lym-1

N/A

Report date: 2025/11/18 17:45:24

Base Information

Drug Name90Y-2IT-BAD-Lym-1

Drug Alias Name90Y-2IT-BAD-Lym-1

ClassificationRadiation-emitting products > Nuclides > Yttrium > 90YRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionAnti-CD74

TargetsHLA-DR antigens-associated invariant chain

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A